Stock Fundamentals

Company Information

Company Name
Charles River Laboratories
Sector
Healthcare
Industry
Diagnostics & Research
Exchange
NYSE
ISIN: US1598641074
CIK: 0001100682
CUSIP: 159864107
Currency: USD
Full Time Employees: 18,300
Phone: 781 222 6000
Fiscal Year End: December
IPO Date: Jun 23, 2000
Description:

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including genetically engineered models and services, insourcing solutions, and research animal diagnostic services; and engages in development and production of cell therapies. The Discovery and Safety Assessment segment offers in vitro and in vivo discovery services for the discovery, development, and safety testing of novel drugs, molecule compounds, oligonucleotides, and biotherapeutics, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services; and vivarium space services. The Manufacturing Solutions segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products; offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and contract development and manufacturing products and services. The company has strategic collaborations with Parker Institute for Cancer Immunotherapy and Children's Hospital Los Angeles across its contract development and manufacturing organization. Additionally, it has a strategic alliance with Francis Crick Institute (Crick), Inc. for the development of Antibody-Drug Conjugate (ADC) drug discovery and development. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Address:

251 Ballardvale Street, Wilmington, MA, United States, 01887

Directors & Officers

Name Title Year Born
Ms. Birgit Girshick CEO & Director 1970
Mr. Michael Gunnar Knell Corporate Senior VP & Chief Accounting Officer 1977
Mr. Joseph W. LaPlume J.D. Corporate Executive Vice President of Corporate Development & Strategy 1974
Ms. Victoria L. Creamer Corporate Executive VP & Chief People Officer 1970
Mr. Glenn G. Coleman CPA Corporate Executive VP & CFO 1968
Prof. Julie Frearson Ph.D. Corporate Senior VP & Chief Scientific Officer NA
Mr. Mark Mintz Corporate EVP, Chief Information Officer & Global Shared Services 1974
Mr. Todd Spencer Corporate Vice President of Investor Relations NA
Ms. Kerry Dailey Corporate Senior VP & Chief Legal Officer NA
Ms. Amy E. Cianciaruso Corporate Senior Vice President, Chief Communications Officer & Government Relations NA

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Mar 30, 2026 Ro Khanna N/A Purchase N/A $160.05 N/A
Feb 05, 2026 Ro Khanna N/A Sale N/A $183.58 N/A
Aug 22, 2025 Joseph W Laplume N/A Sale 400.00 $163.72 $65.49K
Aug 18, 2025 Joseph W Laplume N/A Sale 800.00 $157.60 $126.08K
Aug 07, 2025 Joseph W Laplume N/A Sale 400.00 $150.04 $60.02K
May 15, 2025 Robert Bresnahan, Jr. N/A Sale N/A $138.67 N/A
May 14, 2025 George Massaro N/A Sale 140.00 $140.73 $19.70K
May 13, 2025 Joseph W Laplume N/A Sale 500.00 $145.41 $72.71K

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
Vanguard Group Inc 5.89M Dec 31, 2025 12.22% $0.02 0.81%
BlackRock Inc 3.86M Mar 31, 2026 8.01% $0.01 2.79%
FMR Inc 3.46M Mar 31, 2026 7.18% $0.03 99.33%
Vanguard Capital Management, LLC 3.20M Mar 31, 2026 6.65% $0.01 0.00%
Amvescap Plc. 2.40M Mar 31, 2026 4.98% $0.06 -11.09%
Vanguard Portfolio Management, LLC 2.29M Mar 31, 2026 4.76% $0.02 0.00%
Harris Associates L.P. 2.15M Mar 31, 2026 4.47% $0.50 28.36%
Allspring Global Investments Holdings, LLC 1.99M Mar 31, 2026 4.14% $0.58 -0.11%
State Street Corp 1.87M Mar 31, 2026 3.89% $0.01 0.10%
Dimensional Fund Advisors, Inc. 1.65M Mar 31, 2026 3.43% $0.06 14.58%
Wellington Management Company LLP 1.63M Mar 31, 2026 3.38% $0.05 -6.85%
Ariel Investments, LLC 1.44M Mar 31, 2026 3.00% $2.79 1.15%
Geode Capital Management, LLC 1.31M Mar 31, 2026 2.71% $0.01 2.29%
Citadel Advisors Llc 1.21M Mar 31, 2026 2.52% $0.03 190.32%
Bank of America Corp 1.14M Mar 31, 2026 2.36% $0.01 5.04%
T. Rowe Price Associates, Inc. 1.13M Mar 31, 2026 2.34% $0.02 1,444.34%
Ameriprise Financial Inc 1.11M Mar 31, 2026 2.30% $0.04 -19.86%
Van Berkom and Associates Inc 1.00M Mar 31, 2026 2.08% $2.83 122.39%
Earnest Partners LLC 971.37K Mar 31, 2026 2.02% $0.69 -1.71%
Millennium Management LLC 934.05K Mar 31, 2026 1.94% $0.07 182.95%

Shares Statistics

Shares Outstanding: 48.17M
Shares Float: 47.58M
% Insiders: 63.60%
% Institutions: 12,340.00%
Short % Float: 9.34%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Vanguard Total Stock Mkt Idx Inv 1.57M 3.26% ▲ 0.25% Apr 30, 2026
2 Fidelity Contrafund 1.46M 3.04% ▲ 6.55% Apr 30, 2026
3 Allspring Special US Mid Cap Value Eq 1.45M 3.02% ▼ 8.99% Mar 31, 2026
4 Allspring Special Mid Cap Value Inst 1.45M 3.02% ▲ 0.00% Apr 30, 2026
5 Oakmark Select Investor 1.40M 2.90% ▲ 39.24% Mar 31, 2026
6 Vanguard 500 Index Investor 1.28M 2.65% ▲ 1.81% Apr 30, 2026
7 Vanguard Small Cap Index 1.13M 2.35% ▼ 0.24% Apr 30, 2026
8 Invesco S&P 500® Equal Weight ETF 994.33K 2.06% ▲ 0.19% May 29, 2026
9 Vanguard Small Cap Value Index Inv 728.85K 1.51% ▲ 0.77% Apr 30, 2026
10 Vanguard Windsor Investor Shares 668.85K 1.39% ▼ 27.59% Mar 31, 2026

Valuation Metrics

Enterprise Value: $11.90B
Trailing P/E: 0.00
Forward P/E: 16.84

Financial Highlights

Market Cap: $9.03B
EBITDA: $889.62M
PEG Ratio: $0.12
Book Value: $61.05
Earnings/Share: $-3.71
Profit Margin: -4.59%
Operating Margin: 15.92%
ROA (TTM): 4.26%
ROE (TTM): -5.87%
Revenue (TTM): $4.03B
Revenue/Share (TTM): $81.96
Earnings Growth (YOY): -17.30%
Revenue Growth (YOY): 1.20%

Stock Price History

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

Revenue & Net Income (Yearly)

Revenue & Net Income (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Earnings Per Share (EPS) History

Financial Ratios

Balance Sheet (Yearly)

Financial Ratios

Date Current Ratio Debt/Equity Debt/Assets Interest Coverage Debt/EBITDA
2025-12-31 1.29x 0.69x 0.55x 4.74x 5.29x
2024-12-31 1.41x 0.68x 0.53x 1.80x 4.05x
2023-12-31 1.52x 0.86x 0.55x 4.52x 2.99x
2022-12-31 1.32x 0.93x 0.60x 10.98x 2.80x
2021-12-31 1.23x 1.06x 0.63x 7.98x 3.26x
2020-12-31 1.43x 0.94x 0.61x 5.01x 2.57x
2019-12-31 1.44x 1.15x 0.64x 5.77x 3.34x
2018-12-31 1.61x 1.27x 0.65x 5.20x 3.29x
2017-12-31 1.78x 1.10x 0.64x 9.68x 2.50x
2016-12-31 1.53x 1.48x 0.69x 8.57x 3.27x
2015-12-31 1.79x 1.18x 0.63x 13.70x 2.83x
2014-12-31 2.05x 1.16x 0.63x 14.87x 2.72x
2013-12-31 2.24x 1.04x 0.60x 7.22x 2.59x
2012-12-31 1.42x 1.11x 0.62x 4.97x 2.73x
2011-12-31 1.96x 1.36x 0.66x 4.23x 2.76x
2010-12-31 2.13x 1.02x 0.60x -8.76x -3.42x
2009-12-31 2.38x 0.37x 0.38x 7.82x 1.93x
2008-12-31 2.05x 0.48x 0.44x -32.11x -1.62x
2007-12-31 2.01x 0.27x 0.34x 15.32x 1.58x
2006-12-31 1.93x 0.36x 0.37x 0.97x 2.09x
2005-12-31 1.35x 0.16x 0.28x 8.17x 1.08x
2004-12-31 1.46x 0.47x 0.44x 18.26x 3.40x
2003-12-31 3.24x 0.53x 0.41x 21.13x 1.45x
2002-12-31 2.45x 0.73x 0.46x 4.47x 1.75x
2001-12-31 2.13x 0.54x 0.47x 3.31x 1.32x
2000-12-31 1.86x 1.74x 0.68x 0.97x 2.42x
1999-12-31 1.29x -0.03x 1.30x 5.19x 0.06x
1998-12-31 1.56x 0.00x 0.28x 16.68x 0.01x

📦 Raw API Data (JSON Explorer)

Watchlist

0

No stocks in watchlist

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about CRL.US!